Pharmazolin with Mint and Eucalyptus Nasal Spray, solution, 1 mg/mL, 10 mL per bottle.
Ingredients
Active ingredient: xylometazoline hydrochloride;
1 mL of the product contains 1 mg of xylometazoline hydrochloride, calculated as 100% anhydrous substance;
Excipients: eucalyptus oil; peppermint oil; benzalkonium chloride; disodium edetate; propylene glycol; polyethylene glycol 1500; povidone; hypromellose; polysorbate 20; sodium hydrophosphate, dodecahydrate; potassium dihydrogenphosphate; sorbitol (E 420); water for injection.
Dosage Form
Nasal spray, solution.
Main physical and chemical properties: a clear, slightly yellowish to yellowish liquid with a greenish tint.
Pharmacotherapeutic group
Agents used in diseases of the nasal cavity. Decongestants and other preparations for topical use in diseases of the nasal cavity. Sympathomimetics, simple preparations.
ATC code R01A A07.
Pharmacological Properties
Pharmacodynamics.
Xylometazoline is a sympathomimetic agent that acts on α-adrenergic receptors.
When administered nasally, xylometazoline causes constriction of the blood vessels in the nasal mucosa and adjacent areas of the nasopharynx, thereby eliminating edema and hyperemia of the nasal mucosa and nasopharynx, as well as reducing the associated increased mucus secretion and facilitating the removal of blocked nasal secretions, which leads to the clearing of the nasal passages and easier nasal breathing.
The drug’s effect begins within 2 minutes of application and lasts up to 12 hours.
The medication is well tolerated, including by patients with sensitive mucous membranes, and does not impair mucociliary function. Laboratory test results have shown that xylometazoline reduces the infectious activity of the human rhinovirus, which is associated with the common cold.
Thanks to its moisturizing ingredients (sorbitol, hypromellose), Pharmazolin® with Mint and Eucalyptus nasal spray helps relieve dryness and irritation of the nasal mucosa. The product has a balanced pH within the range typical of the nasal cavity.
Xylometazoline has no mutagenic properties. Furthermore, animal studies have not revealed any teratogenic effects of xylometazoline.
Pharmacokinetics.
When applied topically, the medication is hardly absorbed; xylometazoline concentrations in blood plasma are so low that they are virtually undetectable (plasma concentrations are close to the limit of detection).
Indications
Symptomatic treatment of nasal congestion associated with the common cold, hay fever, other allergic rhinitis, and sinusitis.
To facilitate the drainage of secretions in diseases of the paranasal sinuses.
Adjuvant therapy in cases of otitis media (to reduce mucosal edema).
To facilitate rhinoscopy.
Contraindications
Hypersensitivity to xylometazoline or any other component of the medication, angle-closure glaucoma, a history of transsphenoidal hypophysectomy or transnasal or transoral surgical procedures involving exposure of the meninges, rhinitis sicca, or atrophic rhinitis.
Interactions with Other Medications and Other Types of Interactions
Monoamine oxidase inhibitors (MAOIs): Xylometazoline may potentiate the effects of MAOIs and induce a hypertensive crisis. Do not administer xylometazoline to patients who are taking or have taken MAO inhibitors within the past two weeks.
Tricyclic and tetracyclic antidepressants: Concomitant use of tricyclic or tetracyclic antidepressants with sympathomimetic agents may enhance the sympathomimetic effect of xylometazoline; therefore, the concurrent use of such agents is not recommended.
When used in combination with β-blockers, it may cause bronchospasm or a decrease in blood pressure.
Special Considerations for Use
The drug should not be used for more than 7 consecutive days. Excessively prolonged or excessive use may lead to the development of medication-induced rhinitis, characterized by the recurrence of nasal congestion—that is, symptoms similar to a cold—and/or atrophy of the nasal mucosa.
Like other sympathomimetics, this medication should be prescribed with caution to patients who have severe reactions to adrenergic agents, manifested as insomnia, dizziness, tremors, cardiac arrhythmia, or increased blood pressure.
The recommended dose should not be exceeded, especially when treating children and the elderly.
The drug should be prescribed with caution to patients with cardiovascular diseases, hypertension, diabetes mellitus, hyperthyroidism, pheochromocytoma, benign prostatic hyperplasia; it should also not be used during concomitant treatment with MAO inhibitors or within 2 weeks after discontinuation of such treatment.
Patients with long QT syndrome who are receiving xylometazoline may be at increased risk of serious ventricular arrhythmias.
The product contains benzalkonium chloride, which may cause irritation and skin reactions.
The product contains propylene glycol, which may cause skin irritation.
Use during pregnancy or breastfeeding.
This medication should not be used during pregnancy due to its potential vasoconstrictive effect.
There is no evidence of any adverse effects on the infant. It is unknown whether xylometazoline is excreted in breast milk; therefore, caution is advised, and the medication should be used during breastfeeding only as directed by a doctor.
Fertility.
There are no adequate data on the effect of Pharmazolin® with mint and eucalyptus on fertility. Since systemic exposure to xylometazoline hydrochloride is very low, the likelihood of an effect on fertility is extremely low.
Effect on reaction time when driving or operating machinery.
The drug usually has no or only a minor effect on the ability to drive or operate machinery. If the drug is used for too long or in high doses, its effect on the cardiovascular system cannot be ruled out.
Dosage and Administration
Administer 1 spray into each nostril up to 3 times daily to adults and children 12 years of age and older. Do not use more than 3 sprays in each nostril per day. The duration of treatment depends on the course of the disease and should not exceed 7 consecutive days.
The metered-dose spray ensures accurate dosing and proper distribution of the solution over the surface of the nasal mucosa. Each spray delivers 0.14 g of solution, corresponding to 0.14 mg of xylometazoline.
Before use, prim the dispenser by performing several spray motions until the spray begins to be released into the air. For subsequent use, the dispenser will be ready for immediate use.
Use the spray as follows:
- Thoroughly clean your nose before using the medication;
- Hold the bottle upright, supporting the bottom with your thumb and holding the tip between two fingers;
- Tilt the bottle slightly and insert the tip into your nostril;
- spray the medication and, at the same time, take a light breath in through your nose;
- After use, clean and dry the tip before replacing the cap;
- To prevent infection, each bottle of the medication should be used by only one person.
It is recommended to administer the last dose immediately before bedtime.
Children.
Do not use this medication in children under 12 years of age.
Overdose
Excessive topical application of xylometazoline hydrochloride or its accidental ingestion may lead to severe dizziness, sweating, a significant drop in body temperature, headache, bradycardia, hypertension, respiratory depression, coma, and seizures. Elevated blood pressure may turn into hypotension. Younger children are more sensitive to toxicity than adults.
All patients with suspected overdose should receive appropriate supportive care and, if necessary, emergency symptomatic treatment under medical supervision. Medical care should include monitoring the patient for several hours. In cases of severe overdose accompanied by cardiac arrest, resuscitation efforts should continue for at least 1 hour.
Side Effects
Immune system:
rare (<1/10,000): hypersensitivity reactions, including angioedema, rash, and itching.
Nervous system:
common (≥1/100, <1/10): headache.
Eye disorders:
rare (<1/10,000): temporary visual disturbances.
Cardiovascular system:
rare (<1/10,000): irregular or rapid heartbeat, hypertension, arrhythmia.
Respiratory, thoracic, and mediastinal disorders:
common (≥1/100, <1/10): dryness or discomfort of the nasal mucosa, burning sensation, drug-induced rhinitis;
uncommon (≥ 1/1,000 to <1/100): epistaxis.
Gastrointestinal system:
common (≥1/100, <1/10): nausea.
General disorders and administration site conditions:
common (≥1/100, <1/10): burning sensation at the application site.
Shelf life
2 years.
Do not use this medication after the expiration date printed on the package.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 mL per vial. 1 vial per pack.
Dispensing Category
Over-the-counter.
Manufacturer
Farmak JSC.
Similar products
Products from the same category











